Works by Chen, Zhendong

Results: 95
    1
    2
    3
    4
    5
    6

    Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double‐Blinded, Placebo‐Controlled, Randomized Phase III Trial (ALTER0703).

    Published in:
    Oncologist, 2021, v. 26, n. 10, p. e1693, doi. 10.1002/onco.13857
    By:
    • Chi, Yihebali;
    • Shu, Yongqian;
    • Ba, Yi;
    • Bai, Yuxian;
    • Qin, Baoli;
    • Wang, Xiuwen;
    • Xiong, Jianping;
    • Xu, Nong;
    • Zhang, Helong;
    • Zhou, Jianfeng;
    • Xu, Jianming;
    • Cheng, Ying;
    • Feng, Jifeng;
    • Hu, Chunhong;
    • Chen, Yigui;
    • Chen, Zhendong;
    • Wang, Jufeng;
    • Dang, Chengxue;
    • Wang, Jianhong;
    • Wan, Yiye
    Publication type:
    Article
    7
    8

    A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394.

    Published in:
    Liver Cancer (2235-1795), 2024, v. 13, n. 4, p. 389, doi. 10.1159/000535338
    By:
    • Qin, Shukui;
    • Fang, Weijia;
    • Ren, Zhenggang;
    • Ou, Shuangyan;
    • Lim, Ho Yeong;
    • Zhang, Feng;
    • Lee, Kin Chung;
    • Choi, Hye Jin;
    • Tong, Jiandong;
    • Tao, Min;
    • Xu, Aibing;
    • Cheng, Ashley;
    • Lu, Chang-Hsien;
    • Chiu, Chang-Fang;
    • Wahid, Mohamed Ibrahim Abdul;
    • Kamble, Shital;
    • Norquist, Josephine M.;
    • Zhong, Wenyan;
    • Li, Chen;
    • Chen, Zhendong
    Publication type:
    Article
    9
    10
    11
    12

    Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-56096-2
    By:
    • Xu, Binghe;
    • Zhang, Qingyuan;
    • Luo, Yang;
    • Tong, Zhongsheng;
    • Sun, Tao;
    • Shan, Changping;
    • Liu, Xinlan;
    • Yao, Yumin;
    • Zhao, Bing;
    • Wang, Shusen;
    • Zeng, Xiaohua;
    • Hu, Changlu;
    • Yan, Xi;
    • Wang, Xiaojia;
    • Jia, Hongyan;
    • Chen, Zhendong;
    • Qiu, Fuming;
    • Wu, Xinhong;
    • Zhang, Deyong;
    • Li, Tong
    Publication type:
    Article
    13
    14

    Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial.

    Published in:
    Advances in Therapy, 2020, v. 37, n. 11, p. 4585, doi. 10.1007/s12325-020-01477-w
    By:
    • Li, Jin;
    • Guo, Weijian;
    • Bai, Yuxian;
    • Deng, Yanhong;
    • Yang, Lei;
    • Chen, Zhendong;
    • Zhong, Haijun;
    • Xu, Ruihua;
    • Pan, Hongming;
    • Shu, Yongqian;
    • Yuan, Ying;
    • Zhou, Jianfeng;
    • Xu, Nong;
    • Liu, Tianshu;
    • Ma, Dong;
    • Wu, Changping;
    • Cheng, Ying;
    • Xu, Jianming;
    • Chen, Donghui;
    • Li, Wei
    Publication type:
    Article
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30

    ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer.

    Published in:
    Signal Transduction & Targeted Therapy, 2025, v. 10, n. 1, p. 1, doi. 10.1038/s41392-025-02149-3
    By:
    • Hu, Xichun;
    • Zhang, Qingyuan;
    • Wang, Leiping;
    • Zhang, Jian;
    • Ouyang, Quchang;
    • Wang, Xiaojia;
    • Li, Wei;
    • Xie, Weimin;
    • Tong, Zhongsheng;
    • Wang, Shusen;
    • Xu, Faliang;
    • Sun, Tao;
    • Liu, Wei;
    • Chen, Zhendong;
    • Wu, Jinsheng;
    • Wang, Ying;
    • Wang, Haixia;
    • Yan, Min;
    • Wang, Xinshuai;
    • Wang, Jingfen
    Publication type:
    Article
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44

    Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.

    Published in:
    Cancer Immunology, Immunotherapy, 2024, v. 73, n. 7, p. 1, doi. 10.1007/s00262-024-03677-7
    By:
    • Zhang, Panpan;
    • Chen, Zhendong;
    • Shi, Si;
    • Li, Zhiping;
    • Ye, Feng;
    • Song, Lijie;
    • Zhang, Yanqiao;
    • Yin, Fei;
    • Zhang, Xing;
    • Xu, Jianming;
    • Cheng, Ying;
    • Su, Weiguo;
    • Shi, Michael;
    • Fan, Songhua;
    • Tan, Panfeng;
    • Zhong, Chen;
    • Lu, Ming;
    • Shen, Lin
    Publication type:
    Article
    45
    46
    47

    Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 22, p. 20847, doi. 10.1002/cam4.6664
    By:
    • Chen, Likun;
    • Rangel, Jose David Gomez;
    • Cil, Timucin;
    • Li, Xingya;
    • Cicin, Irfan;
    • Shen, Yihong;
    • Liu, Zhihua;
    • Ozyilkan, Ozgur;
    • Igor, Bondarenko;
    • Chen, Jun;
    • Oleksandr, Kostiuk;
    • Chen, Zhendong;
    • Zhang, Helong;
    • Fu, Ziyi;
    • Dong, Qingfeng;
    • Song, Shuqiang;
    • Yu, Jin‐Chen;
    • Zhang, Li;
    • Hryhoriy, Adamchuk;
    • Karaoglu, Aziz
    Publication type:
    Article
    48
    49
    50

    Thyroid Function Abnormalities in COVID-19 Patients.

    Published in:
    Frontiers in Endocrinology, 2021, v. 11, p. N.PAG, doi. 10.3389/fendo.2020.623792
    By:
    • Wang, Weibin;
    • Su, Xingyun;
    • Ding, Yongfeng;
    • Fan, Weina;
    • Zhou, Weibin;
    • Su, Junwei;
    • Chen, Zhendong;
    • Zhao, Hong;
    • Xu, Kaijin;
    • Ni, Qin;
    • Xu, Xiaowei;
    • Qiu, Yunqing;
    • Teng, Lisong
    Publication type:
    Article